Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count
Research output: Contribution to journal › Journal article › Research › peer-review
Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
| Original language | English |
|---|---|
| Journal | Clinical Infectious Diseases |
| Volume | 51 |
| Issue number | 5 |
| Pages (from-to) | 611-9 |
| Number of pages | 9 |
| ISSN | 1058-4838 |
| DOIs | |
| Publication status | Published - 1 Sep 2010 |
- AIDS-Related Opportunistic Infections, Adult, Anti-HIV Agents, Antifungal Agents, CD4 Lymphocyte Count, Europe, Female, HIV Infections, Humans, Incidence, Male, Middle Aged, Pneumocystis jirovecii, Pneumonia, Pneumocystis, Risk Factors
Research areas
ID: 33863666